NeoGenomics Appoints Abhishek Jain to CFO Role

Dow Jones01-12
 

By Adriano Marchese

 

NeoGenomics appointed Abhishek Jain to the role of chief financial officer, succeeding Jeff Sherman, who is set to retire from the position in March.

Jain brings to the cancer-diagnostics company a wealth of experience in the life sciences sector, most recently as CFO of CareDx, a publicly traded precision medicine company, for the past three years.

Prior to that, Jain served for nearly 20 years in finance and accounting roles of increasing responsibility at Agilent Technologies, an analytical and clinical laboratory technologies company.

Jain's appointment to the CFO position is effective on March 2, which is when Sherman is set to officially retire.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

January 12, 2026 07:40 ET (12:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment